436 related articles for article (PubMed ID: 32676080)
1. "Small" Intestinal Immunopathology Plays a "Big" Role in Lethal Cytokine Release Syndrome, and Its Modulation by Interferon-γ, IL-17A, and a Janus Kinase Inhibitor.
Kale SD; Mehrkens BN; Stegman MM; Kastelberg B; Carnes H; McNeill RJ; Rizzo A; Karyala SV; Coutermarsh-Ott S; Fretz JA; Sun Y; Koff JL; Rajagopalan G
Front Immunol; 2020; 11():1311. PubMed ID: 32676080
[TBL] [Abstract][Full Text] [Related]
2. Interferon gamma-dependent intestinal pathology contributes to the lethality in bacterial superantigen-induced toxic shock syndrome.
Tilahun AY; Holz M; Wu TT; David CS; Rajagopalan G
PLoS One; 2011 Feb; 6(2):e16764. PubMed ID: 21304813
[TBL] [Abstract][Full Text] [Related]
3. IFN-
Sun Y; Hu B; Stanley G; Harris ZM; Gautam S; Homer R; Koff JL; Rajagopalan G
Am J Respir Cell Mol Biol; 2023 Jan; 68(1):75-89. PubMed ID: 36125351
[TBL] [Abstract][Full Text] [Related]
4. IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome.
Kang S; Tanaka T; Inoue H; Ono C; Hashimoto S; Kioi Y; Matsumoto H; Matsuura H; Matsubara T; Shimizu K; Ogura H; Matsuura Y; Kishimoto T
Proc Natl Acad Sci U S A; 2020 Sep; 117(36):22351-22356. PubMed ID: 32826331
[TBL] [Abstract][Full Text] [Related]
5. The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.
Goker Bagca B; Biray Avci C
Cytokine Growth Factor Rev; 2020 Aug; 54():51-62. PubMed ID: 32636055
[TBL] [Abstract][Full Text] [Related]
6. Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19.
Luo W; Li YX; Jiang LJ; Chen Q; Wang T; Ye DW
Trends Pharmacol Sci; 2020 Aug; 41(8):531-543. PubMed ID: 32580895
[TBL] [Abstract][Full Text] [Related]
7. Systemic inflammatory response elicited by superantigen destabilizes T regulatory cells, rendering them ineffective during toxic shock syndrome.
Tilahun AY; Chowdhary VR; David CS; Rajagopalan G
J Immunol; 2014 Sep; 193(6):2919-30. PubMed ID: 25092888
[TBL] [Abstract][Full Text] [Related]
8. Janus kinase signaling as risk factor and therapeutic target for severe SARS-CoV-2 infection.
Solimani F; Meier K; Ghoreschi K
Eur J Immunol; 2021 May; 51(5):1071-1075. PubMed ID: 33675065
[TBL] [Abstract][Full Text] [Related]
9. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
Liu B; Li M; Zhou Z; Guan X; Xiang Y
J Autoimmun; 2020 Jul; 111():102452. PubMed ID: 32291137
[TBL] [Abstract][Full Text] [Related]
10. MAIT cells launch a rapid, robust and distinct hyperinflammatory response to bacterial superantigens and quickly acquire an anergic phenotype that impedes their cognate antimicrobial function: Defining a novel mechanism of superantigen-induced immunopathology and immunosuppression.
Shaler CR; Choi J; Rudak PT; Memarnejadian A; Szabo PA; Tun-Abraham ME; Rossjohn J; Corbett AJ; McCluskey J; McCormick JK; Lantz O; Hernandez-Alejandro R; Haeryfar SMM
PLoS Biol; 2017 Jun; 15(6):e2001930. PubMed ID: 28632753
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.
Yeleswaram S; Smith P; Burn T; Covington M; Juvekar A; Li Y; Squier P; Langmuir P
Clin Immunol; 2020 Sep; 218():108517. PubMed ID: 32585295
[TBL] [Abstract][Full Text] [Related]
12. Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids.
Miao Y; Fan L; Li JY
Front Immunol; 2020; 11():1445. PubMed ID: 32612616
[No Abstract] [Full Text] [Related]
13. Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines.
Fara A; Mitrev Z; Rosalia RA; Assas BM
Open Biol; 2020 Sep; 10(9):200160. PubMed ID: 32961074
[TBL] [Abstract][Full Text] [Related]
14. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.
La Rosée F; Bremer HC; Gehrke I; Kehr A; Hochhaus A; Birndt S; Fellhauer M; Henkes M; Kumle B; Russo SG; La Rosée P
Leukemia; 2020 Jul; 34(7):1805-1815. PubMed ID: 32518419
[TBL] [Abstract][Full Text] [Related]
15. The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response.
Arnaldez FI; O'Day SJ; Drake CG; Fox BA; Fu B; Urba WJ; Montesarchio V; Weber JS; Wei H; Wigginton JM; Ascierto PA
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385146
[TBL] [Abstract][Full Text] [Related]
16. The impact of tacrolimus on the immunopathogenesis of staphylococcal enterotoxin-induced systemic inflammatory response syndrome and pneumonia.
Tilahun AY; Karau MJ; Clark CR; Patel R; Rajagopalan G
Microbes Infect; 2012 Jun; 14(6):528-36. PubMed ID: 22273732
[TBL] [Abstract][Full Text] [Related]
17. Perspectives on Targeting IL-6 as a Potential Therapeutic Strategy for COVID-19.
Khaedir Y; Kartika R
J Interferon Cytokine Res; 2021 Feb; 41(2):37-43. PubMed ID: 33621130
[TBL] [Abstract][Full Text] [Related]
18. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib.
Wu D; Yang XO
J Microbiol Immunol Infect; 2020 Jun; 53(3):368-370. PubMed ID: 32205092
[TBL] [Abstract][Full Text] [Related]
19. Rapid and Rigorous IL-17A Production by a Distinct Subpopulation of Effector Memory T Lymphocytes Constitutes a Novel Mechanism of Toxic Shock Syndrome Immunopathology.
Szabo PA; Goswami A; Mazzuca DM; Kim K; O'Gorman DB; Hess DA; Welch ID; Young HA; Singh B; McCormick JK; Haeryfar SM
J Immunol; 2017 Apr; 198(7):2805-2818. PubMed ID: 28219889
[TBL] [Abstract][Full Text] [Related]
20. Immunological analysis of the murine anti-CD3-induced cytokine release syndrome model and therapeutic efficacy of anti-cytokine antibodies.
Nouveau L; Buatois V; Cons L; Chatel L; Pontini G; Pleche N; Ferlin WG
Eur J Immunol; 2021 Aug; 51(8):2074-2085. PubMed ID: 33945643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
